National Cancer Act of 2007 - Amends the Public Health Service Act to require the Director of the National Cancer Institute to establish a loan repayment program for health professionals agreeing to engage in cancer prevention research.
Provides for research on cancer treatments that target cancer cells, the cancer care workforce, cancer survivorship, environmental risk factors for cancer, and treatment disparities.
Requires the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention (CDC), to carry out demonstration programs on: (1) lung cancer early detection using Computer Tomography (CT) scanning; and (2) colorectal screening.
Amends the Federal Food, Drug, and Cosmetic Act to set forth provisions for chemoprevention drugs that: (1) allow the Secretary to designate such drugs; and (2) provide market exclusivity for seven years for approved drugs or licensed biological products. Defines "chemoprevention drug" as a drug designed to treat a high-risk medical condition that: (1) has been diagnosed in individuals who have not been diagnosed with cancer or who do not currently have progressive, life-threatening cancer; and (2) unless treated, could develop into progressive and life-threatening cancer.
Establishes the ChemoPrevention Products Board to develop chemoprevention drugs and devices.
Requires the Secretary to establish a program to expand access to investigational treatments for individuals diagnosed with cancer.
Amends title XVIII (Medicare) of the Social Security Act to provide coverage for cancer care coordinators who provide overall coordination and management of the medical, nursing, and other health services provided to individuals diagnosed with cancer.
Allows a biorepository to adopt specified guidelines for the collection of biospecimens. Requires the Medicare Payment Assessment Commission (MedPAC) to report to Congress on developing a payment system for collecting and storing cancer tissue for research.